- ISIN
- US4268971045
- CUSIP
- 426897104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 11, 2014
Highlights
- Market Cap
- $534.45K
- Enterprise Value
- -$2.07M
- EPS (TTM)
- -$0.27
- EBITDA (TTM)
- -$2.97M
- Year Range
- $0.03 - $0.11
- Target Price
- $70.00
- ROA (TTM)
- -110.25%
- ROE (TTM)
- -160.64%
- Avg. Volume (1M)
- 35K
- Avg. Volume Value (1M)
- $1.76K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
HEPA Performance Chart
Hepion Pharmaceuticals, Inc. (HEPA) is down 23.5% since the beginning of the year. At $0 per share, HEPA is trading 58.3% below its 52-week high of $0. Investors who bought $1,000 worth of HEPA shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Hepion Pharmaceuticals, Inc. (HEPA) has returned -23.50% so far this year and 6.99% over the past 12 months. Over the last ten years, HEPA has returned -80.44% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Hepion Pharmaceuticals, Inc.
- 1D
- -0.22%
- 1M
- -45.16%
- 6M
- 32.28%
- YTD
- -23.50%
- 1Y
- 6.99%
- 3Y*
- -95.16%
- 5Y*
- -87.56%
- 10Y*
- -80.44%
- ALL TIME*
- -74.18%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
HEPA Monthly Returns History
Based on dividend-adjusted daily data since Feb 11, 2014, HEPA's average daily return is -0.16%, while the average monthly return is -4.99%.
Historically, 34% of months were positive and 66% were negative. The best month was Jan 2023 with a return of +143.0%, while the worst month was Mar 2025 at -93.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, HEPA closed higher 41% of trading days. The best single day was Oct 5, 2015 with a return of +123.7%, while the worst single day was Jan 22, 2025 at -58.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -42.17% | 15.27% | 42.00% | 10.04% | 5.81% | 2.60% | -32.35% | -23.50% | |||||
| 2025 | -61.82% | -29.81% | -93.18% | -32.68% | -80.96% | 45.19% | -47.50% | 58.81% | -25.04% | 33.70% | -2.77% | -7.69% | -99.74% |
| 2024 | -41.36% | 56.32% | -16.16% | -45.18% | -7.69% | -19.04% | -23.26% | 7.05% | -20.05% | -1.63% | 1.36% | -29.63% | -85.49% |
| 2023 | 143.02% | 19.69% | -11.10% | -10.43% | -30.98% | 9.38% | -24.29% | -6.29% | -33.02% | -6.41% | -31.05% | 0.62% | -46.05% |
| 2022 | -14.03% | 12.23% | 17.27% | -28.12% | -15.86% | -26.61% | -5.68% | 26.43% | -26.00% | 5.40% | -31.42% | -17.77% | -73.66% |
| 2021 | -5.94% | -8.74% | -2.13% | -5.98% | -1.73% | 16.47% | -22.22% | 4.55% | -4.97% | -6.54% | -13.29% | -8.06% | -47.95% |
Benchmark Metrics
Hepion Pharmaceuticals, Inc. has an annualized alpha of -38.39%, beta of 0.71, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 11, 2014.
- This stock participated in 254.95% of S&P 500 Index downside but only -130.00% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -38.39%
- Beta
- 0.71
- R²
- 0.01
- Upside Capture
- -130.00%
- Downside Capture
- 254.95%
Return for Risk
Risk / Return Rank
HEPA ranks 60 for risk / return — above 60% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Hepion Pharmaceuticals, Inc. (HEPA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HEPA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.38 | ||
| Sortino ratioReturn per unit of downside risk | +0.14 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.25 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 0.15 | 2.00 | -1.85 |
| Martin ratioReturn relative to average drawdown | 0.27 | 8.49 | -8.22 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Hepion Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Hepion Pharmaceuticals, Inc. was 100.00%, occurring on Jan 30, 2026. The portfolio has not yet recovered.
The current Hepion Pharmaceuticals, Inc. drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Jan 2026 | 10y 6mo | — | 11y 29dJul 2015 - now | — |
-78.04%Oct 2014 | 6mo 23d | 3mo 23d | 10mo 16dMar 2014 - Feb 2015 | — |
-40.00%Feb 2014 | 7d | 18d | 25dFeb 2014 - Mar 2014 | — |
-39.22%Apr 2015 | 2mo 19d | 2mo 2d | 4mo 21dFeb 2015 - Jun 2015 | — |
-13.08%Mar 2014 | 1d | 9d | 10dMar 2014 - Mar 2014 | — |
Drawdown Indicators
| HEPA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -61.44% | -9.10% | -52.34% |
Max Drawdown (3Y)Largest decline over 3 years | -99.99% | -18.90% | -81.09% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | -1.58% | -98.42% |
Average DrawdownAverage peak-to-trough decline | -87.64% | -10.70% | -76.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.61% | 2.14% | +32.47% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Hepion Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Hepion Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HEPA in comparison with other companies in the Biotechnology industry. Currently, HEPA has a P/B value of 0.5. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with HEPA
Add Hepion Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with HEPA